drugset / Trial / NCT06819735
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Phase 1/2
Recruiting
125 enrolled
Domain Therapeutics Australia Pty Ltd
Domain Therapeutics SA · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1/2, dose-escalation, clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibody) as a single agent and in combination with an immune checkpoint inhibitor in adult participants with selected advanced solid tumors.
Timeline
- Start
- 2025-06-25
- Primary completion
- 2027-09
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DT-7012 | Monoclonal antibody | — | Intravenous |